Product Description: Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM[1][2].
Applications: Cancer-Kinase/protease
Formula: C23H20N6O
References: [1]Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658./[2]Hibiki Udagawa, et al. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res. 2019 Nov;17(11):2233-2243.
CAS Number: 1661854-97-2
Molecular Weight: 396.44
Compound Purity: 99.81
Research Area: Cancer
Solubility: DMSO : 22.73 mg/mL (ultrasonic)
Target: Apoptosis;EGFR
Deutsch
English
